834 related articles for article (PubMed ID: 16399206)
1. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
2. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
3. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Tang WJ
Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
[TBL] [Abstract][Full Text] [Related]
4. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
Edland SD
J Mol Neurosci; 2004; 23(3):213-7. PubMed ID: 15181249
[TBL] [Abstract][Full Text] [Related]
5. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.
Cook DG; Leverenz JB; McMillan PJ; Kulstad JJ; Ericksen S; Roth RA; Schellenberg GD; Jin LW; Kovacina KS; Craft S
Am J Pathol; 2003 Jan; 162(1):313-9. PubMed ID: 12507914
[TBL] [Abstract][Full Text] [Related]
6. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
Farris W; Mansourian S; Leissring MA; Eckman EA; Bertram L; Eckman CB; Tanzi RE; Selkoe DJ
Am J Pathol; 2004 Apr; 164(4):1425-34. PubMed ID: 15039230
[TBL] [Abstract][Full Text] [Related]
7. Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.
Keeney JT; Ibrahimi S; Zhao L
J Alzheimers Dis; 2015; 48(2):411-24. PubMed ID: 26402005
[TBL] [Abstract][Full Text] [Related]
8. Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.
Kochkina EG; Plesneva SA; Vasilev DS; Zhuravin IA; Turner AJ; Nalivaeva NN
Biogerontology; 2015 Aug; 16(4):473-84. PubMed ID: 25792373
[TBL] [Abstract][Full Text] [Related]
9. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models.
Stargardt A; Gillis J; Kamphuis W; Wiemhoefer A; Kooijman L; Raspe M; Benckhuijsen W; Drijfhout JW; Hol EM; Reits E
Aging Cell; 2013 Jun; 12(3):499-507. PubMed ID: 23534431
[TBL] [Abstract][Full Text] [Related]
10. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
11. Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease.
Li G; Kim C; Kim J; Yoon H; Zhou H; Kim J
J Alzheimers Dis; 2015; 46(1):109-22. PubMed ID: 25720399
[TBL] [Abstract][Full Text] [Related]
12. Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Haque R; Nazir A
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2454-2462. PubMed ID: 27443962
[TBL] [Abstract][Full Text] [Related]
13. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
[TBL] [Abstract][Full Text] [Related]
14. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348
[TBL] [Abstract][Full Text] [Related]
15. Beta-amyloid deposition in brains of subjects with diabetes.
Alafuzoff I; Aho L; Helisalmi S; Mannermaa A; Soininen H
Neuropathol Appl Neurobiol; 2009 Feb; 35(1):60-8. PubMed ID: 18346114
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
17. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Pivovarova O; Höhn A; Grune T; Pfeiffer AF; Rudovich N
Ann Med; 2016 Dec; 48(8):614-624. PubMed ID: 27320287
[TBL] [Abstract][Full Text] [Related]
18. Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Tsuda M; Kobayashi T; Matsuo T; Aigaki T
FEBS Lett; 2010 Jul; 584(13):2916-20. PubMed ID: 20493190
[TBL] [Abstract][Full Text] [Related]
19. Insulin-signaling Pathway Regulates the Degradation of Amyloid β-protein via Astrocytes.
Yamamoto N; Ishikuro R; Tanida M; Suzuki K; Ikeda-Matsuo Y; Sobue K
Neuroscience; 2018 Aug; 385():227-236. PubMed ID: 29932983
[TBL] [Abstract][Full Text] [Related]
20. Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1.
Schilling MA
J Alzheimers Dis; 2016; 51(4):961-77. PubMed ID: 26967215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]